{"id":"NCT01069705","sponsor":"Novartis Pharmaceuticals","briefTitle":"Second Open Label Extension to Bridging Study CTBM100C2303","officialTitle":"A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder After Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Patients Who Successfully Completed Participation in Study CTBM100C2303E1","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-02-12","primaryCompletion":"2012-03-19","completion":"2012-03-19","firstPosted":"2010-02-17","resultsPosted":"2021-06-02","lastUpdate":"2021-06-02"},"enrollment":49,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Infections","Pseudomonas Aeruginosa"],"interventions":[{"type":"DRUG","name":"Tobramycin inhalation powder","otherNames":[]}],"arms":[{"label":"Tobramycin Inhalation Powder (TIPnew)","type":"EXPERIMENTAL"}],"summary":"This was an open-label, single arm (uncontrolled) study in participants suffering from cystic fibrosis, who have completed their study participation in CTBM100C2303 and extension study one CTBM100C2303E1 (all visits), who were proven infected with Pseudomonas aeruginosa at enrollment into CTBM100C2303.","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AEs)","timeFrame":"From time of first administration of study drug until study completion (up to 169 days)","effectByArm":[{"arm":"Tobramycin Inhalation Powder (TIPnew)","deltaMin":23,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":17,"countries":["Bulgaria","Estonia","Latvia","Lithuania","Romania","Russia","South Africa"]},"refs":{"pmids":["26709158"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":49},"commonTop":["Respiratory tract infection","Respiratory tract infection viral","Bronchitis","Cough","Hypoacusis"]}}